QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of its License and Option Agreement (LOA) with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace.  The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent (LOI) secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

"Actavis is proving to be an exceptional partner. The strategic synergies between our companies and our collaboration at the joint steering committee level are critical success factors going forward," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.  "With the LOA now complete, we are focusing our ongoing energies towards supporting Actavis as we approach our PDUFA date and prepare for the anticipated launch of our first product, MoxDuo IR, in the third quarter."

Actavis' Chief Executive Officer for the US, Doug Boothe, added:  "Our launch plans for MoxDuo IR are on track and we remain convinced MoxDuo IR is very well suited to the experience and expertise of our marketing and sales teams.  We are very optimistic about the opportunity for MoxDuo IR to successfully penetrate the $2.5 billion acute pain market in the US."

Highlights of the strategic partnership include:

  1. Actavis has exclusive rights to commercialise and further develop MoxDuo IR for the US market while assuming all costs for product launch as well as ongoing marketing and sales efforts in the US. 
  2. Commencing at MoxDuo IR launch, Actavis will pay QRxPharma royalties of 10% to 30% depending on net sales thresholds, except for a period starting 3-6 months following launch where QRxPharma will receive a 50% royalty on US$150 million in cumulative sales.
  3. QRxPharma retains a co-promotion/profit-share right, whereby QRxPharma can create its own sales force and provide up to 25% of the effective selling effort to US prescribers at any time following the first 12 months after product launch.
  4. QRxPharma owns the New Drug Application and is responsible for manufacturing at its contract manufacturer, DSM Pharmaceuticals, Inc.
  5. QRxPharma retains the rights to MoxDuo IR, CR and IV outside the US.

The LOA also provides Actavis an option to negotiate for US marketing and sales rights of MoxDuo CR, a controlled release Dual-Opioid® for chronic pain, as well as MoxDuo IV, a hospital-based intravenous formulation.  Exercise of the option for MoxDuo CR by Actavis is contingent upon achievement of specific MoxDuo IR sales milestones.  The option for MoxDuo IV is time-based with expiry on 31 January 2013.

QRxPharma Limited SOURCE QRxPharma Limited

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triptans better at relieving migraine pain than recently marketed and more expensive drugs